The Overexpression of Bax Produces Cell Death upon Induction of the Mitochondrial Permeability Transition*

John G. Pastorino, Sing-Tsung Chen, Marco Tafani, Jack W. Snyder, and John L. FarberDagger

From the Department of Pathology and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Stably transfected Jurkat T cells were produced in which Bax expression is inducible by muristerone A. The cell death resulting from induction of the overexpression of Bax was prevented by inhibition of the mitochondrial permeability transition (MPT) with cyclosporin A (CyA) in combination with the phospholipase A2 inhibitor aristolochic acid (ArA). The caspase-3 inhibitor Z-Asp-Glu-Val aspartic acid fluoromethylketone (Z-DEVD-FMK) had no effect on the loss of viability. The MPT was measured as the CyA plus ArA-preventable loss of the mitochondrial membrane potential (Delta Psi m). The MPT was accompanied by the release of cytochrome c from the mitochondria, caspase-3 activation in the cytosol, cleavage of the nuclear enzyme poly(ADP-ribose)polymerase (PARP), and DNA fragmentation, all of which were inhibited by CyA plus ArA. Z-DEVD-FMK had no effect on the loss of Delta Psi m and the redistribution of cytochrome c but did prevent caspase-3 activation, PARP cleavage, and DNA fragmentation. It is concluded that Bax induces the MPT, a critical event in the loss of cell viability. In addition to the cell death, the MPT mediates other typical manifestations of apoptosis in this model, namely release of cytochrome c, caspase activation with PARP cleavage, and DNA fragmentation.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Bax is a member of the Bcl-2 family of proteins that has been associated with apoptotic cell death both in cell culture (1) and in intact animals (2). Alterations in mitochondrial function in general and induction of the mitochondrial permeability transition (MPT)1 in particular are proposed to play a critical role in apoptosis (3-5). Bax is localized to mitochondria (6, 7), and the cell death that accompanied the overexpression of Bax was associated with loss of the mitochondrial membrane potential and an increased production of reactive oxygen species (8). However, neither the nature of the responsible mitochondrial alterations nor their relationship to the loss of cell viability and to other features of apoptosis have been defined. Here we show that the induction of the overexpression of Bax in stably transfected Jurkat cells induces the MPT, an event that is accompanied by typical features of apoptosis, namely cytosolic accumulation of cytochrome c, caspase activation, cleavage of poly(ADP-ribose)-polymerase (PARP), DNA fragmentation, and cell death. Inhibition of the MPT prevents all manifestations of apoptosis, whereas caspase inhibition prevents PARP cleavage and DNA fragmentation but not cytochrome c release or cell death.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Generation of Stable Transfectants with Inducible Bax Expression-- Jurkat cells were stably transfected with an inducible expression system encoding mouse Bax. Total RNA was isolated from mouse fibrosarcoma cells (L929). A 5'-primer (5' CCCAAGCTTATGGACGGGTCCGGGGAG 3') and 3'-primer (5'-GGAATTCAGCCCATCTTCTTCCAG 3') were designed and utilized for reverse transcription and polymerase chain reaction amplification of the cDNA for Bax from the isolated total RNA. The polymerase chain reaction products were electrophoresed, and the 579-base pair mouse Bax cDNA was identified. The fragment was then cloned into pIND downstream of the ecdysone response element to generate pINDBax. The insert was sequenced and found to be 100% identical to the published sequence of mouse Bax (GenBankTM accession number L22472). To generate inducible clones, wild-type Jurkat cells were first transfected with pVgRXR, which encodes for a heterodimer of the ecdysone receptor, and the retinoid X receptor, which binds the ecdysone response element (encoded on pINDBax) in the presence of muristerone A. Stable transfectants were obtained (JtVgRXR) and in turn transfected with the pIND(Bax) construct. Stable transfectants (JtBax1 and 2) were then selected. JtLacz1 clones were generated as above with the exception that cDNA for beta -galactosidase was cloned into pIND instead of Bax.

Determination of Bax Expression and PARP Cleavage-- Cells (5 × 105) were pelleted at 700 × g, resuspended in 20 µl of SDS-sample buffer, and boiled for 10 min. Protein content was determined by the bicinchoninic acid assay with bovine serum albumin as a standard. Samples were then run on an 8 or 12% SDS-polyacrylamide electrophoresis gel for determination of PARP cleavage or Bax expression, respectively. Kaleidoscope prestained standards (Bio-Rad) were used to determine molecular weights. The gels were electroblotted onto nitrocellulose membranes. For the determination of PARP cleavage, the blots were probed with anti-human PARP monoclonal antibody (C2-10; Enzyme Systems Products, Dublin, CA) at 1:5,000 dilution. For Bax expression, a rabbit polyclonal anti-Bax antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was used at a 1:2,000 dilution. A secondary horseradish peroxidase-labeled goat-antimouse or goat-antirabbit antibody at 1:2,000 was detected using enhanced chemiluminescence for PARP or Bax, respectively.

Measurements of Cell Viability-- Cell viability was determined by trypan blue exclusion and the ability of viable cells to reduce 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazolium (MTS). For trypan blue exclusion, 10 µl of a 0.5% solution of the dye was added to 100 µl of treated cells (1.0 × 105/ml). The suspension was then applied to a hemocytometer. Both viable and nonviable cells were counted. A minimum of 200 cells were counted for each data point in a total of eight microscopic fields. For the MTS assay, a 100-µl aliquot of cells (1.0 × 106 cells/ml) was placed in the well of a 96-well plate. The reaction was started by the addition of MTS and phenazine methosulfate (PMS). The absorbance change obtained upon reduction of MTS was read 90 min later with a 96-well plate reader at 490 nm. 100% cell killing was determined by the addition of Triton X-100 to a final concentration of 0.5%, 30 min prior to MTS and PMS addition. The MTS assay and trypan blue exclusion gave identical results.

Measurement of Mitochondrial Energization-- Mitochondrial energization was determined as the retention of the dye 3,3'-dihexyloxacarbocyanine (DiOC6(3); Molecular Probes Inc, Eugene, OR). Cells (5 × 105 in 500 µl of complete RPMI 1640 medium) were loaded with 100 nM DiOC6(3) during the last 30 min of treatment. The cells were then pelleted at 700 × g for 10 min. The supernatant was removed, and the pellet was resuspended and washed in PBS two times. The pellet was then lysed by the addition of 600 µl of deionized water followed by homogenization. The concentration of retained DiOC6(3) was read on a Perkin-Elmer LS-5 fluorescence spectrophotometer at 488 nm excitation and 500 nm emission.

Determination of DNA Fragmentation-- Cells (1.0 × 106) were collected by centrifugation at 2,000 × g for 10 min. The cell pellet was washed in PBS and then lysed in 200 µl of 10 mM Tris, pH 8.0, 10 mM EDTA, 0.5% Triton X-100. The lysate was centrifuged at 13,000 × g for 20 min at 4 °C. RNase (0.2 mg/ml) was added, and the lysate was incubated for 30 min at 37 °C. Proteinase K (0.1 mg/ml) and SDS (final concentration 1%) were added, followed by incubation at 50 °C for 16 h. DNA was extracted with phenol/chloroform and then chloroform, precipitated with ethanol and sodium acetate, and electrophoresed on 1.2% agarose gels.

Detection of Caspase-3 Activity-- The assay is based on the ability of the active enzyme to cleave the chromophore pNA from the enzyme substrate DEVD-pNA. Cytosolic fractions isolated as above were diluted 1:1 with 2× reaction buffer (10 mM Tris, pH 7.4, 1 mM dithiothreitol, 2 mM EDTA, 0.1% CHAPS, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml pepstatin, 10 µg/ml leupeptin). DEVD-pNA was added to a final concentration of 50 µM, and the reaction was incubated for 1 h at 37 °C. The samples were then transferred to a 96-well plate, and absorbance measurements were made with a 96-well plate reader at 405 nm.

Isolation of Cytosol and Mitochondrial Fractions and Determination of Cytochrome c Content-- Cells (1.0 × 107) were harvested by centrifugation at 600 × g for 10 min at 4 °C. The cell pellets were washed once in PBS and then resuspended in 3 volumes of isolation buffer (20 mM Hepes, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol, and 10 mM phenylmethylsulfonyl fluoride, 10 µM leupeptin, 10 µM aprotinin) in 250 mM sucrose. After chilling on ice for 3 min, the cells were disrupted by 40 strokes of a glass homogenizer. The homogenate was centrifuged twice at 2,500 × g at 4 °C to remove unbroken cells and nuclei. The mitochondria were then pelleted by centrifugation at 12,000 × g for 30 min. The supernatant was removed and filtered through 0.2 µm and then 0.1 µm Ultrafree MC filters (Millipore) to give cytosolic protein. Mitochondrial and cytosolic fractions (20 µl, 250 µg of protein) were separated on 12% SDS-polyacrylamide electrophoresis gels and electroblotted onto nitrocellulose membranes. Cytochrome c was detected by a monoclonal antibody to cytochrome c (Pharmingen, San Diego, CA) at a dilution of 1:5,000. Secondary goat-antimouse horseradish peroxidase-labeled antibody (1:2000) was detected by enhanced chemiluminescence.

Treatments-- Caspase-3 inhibitor (Z-Asp-Glu-Val aspartic acid fluoromethylketone, Z-DEVD-FMK, Kamiya Biomedical Co. Seattle, WA), was dissolved in Me2SO and added to cells at 50 µM. Cyclosporin A (Biomol Research Laboratories, Plymouth Meeting, PA) was dissolved in dimethyl sulfoxide and added at 5 µM. Aristolochic acid (Biomol) was dissolved in PBS and added at 50 µM. FK506 (Calbiochem, La Jolla, CA) and cypermethrin (Calbiochem) were dissolved in ethanol and added at 5 and 10 µM, respectively. All additions were 1% v/v or less. Control experiments demonstrated that Me2SO and ethanol had no effect on any of the parameters measured under the conditions tested.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

To study the mechanism of action of Bax, we produced clones (JtBax1 and JtBax2) of stably transfected Jurkat T cells in which Bax expression is inducible by muristerone A. Bax was not detected in uninduced JtBax1 cells (Fig. 1a). In the presence of muristerone A, however, Bax expression was detected within 30 min and increased for 4 h (Fig. 1a). Similar results were obtained with JtBax2 cells (data not shown). Bax expression was accompanied by cell death that was detectable within 2 h (Fig. 2a). By 16 h, 75% of the cells were dead. As a control, the cDNA for beta -galactosidase was cloned downstream of the muristerone A-inducible promoter. Stable transfectants (JtLacz1) were produced that, upon induction by muristerone A, exhibited an increase in beta -galactosidase (1000 microunits/106 cells at 6 h). However, induced JtLacz1 cells showed no loss of viability over the same time course that JtBax1 cells were killed (Fig. 2a).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Bax expression in JtBax1 cells. Panel a, at "0" time, 1 µM muristerone A was added to JtBax1. Alternatively, in panel b, 5 µM CyA and 50 µM ArA were added 30 min prior to the addition of muristerone A. In both cases, the time course of Bax expression was determined by Western blot analysis.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   Cell killing upon induction of Bax expression and its inhibition by CyA and ArA. Panel a, JtBax1 (closed circles) and JtLacz1 (closed squares) clones were treated with 1 µM muristerone A. Alternatively in panel b, JtBax1 cells were pretreated with either 5 µM CyA plus 50 µM ArA (closed squares) or 50 µM Z-DEVD-FMK (closed circles) 30 min prior to the addition of muristerone A. Cell viability was determined at the times indicated. All data points are the mean of three independent experiments.

The MPT refers to the regulated opening of a large, nonspecific pore in the inner mitochondrial membrane (9). The MPT is inhibited by cyclosporin A (CyA) (10-12), an effect enhanced and prolonged by phospholipase A2 inhibitors, both in vitro with isolated mitochondria (13) and in the intact cell (14). CyA in combination with the phospholipase inhibitor aristolochic acid (ArA) completely prevented the killing of JtBax1 cells upon induction of Bax expression (Fig. 2b). By contrast, the caspase-3 inhibitor Z-DEVD-FMK (15) had no effect on the loss of viability (Fig. 2b). As a control, the same concentration of Z-DEVD-FMK effectively prevented the killing of JtBax1 cells upon activation of the Fas receptor with an anti-Fas antibody (data not shown). Importantly, CyA plus ArA did not alter the time course or level of Bax expression induced by muristerone A (Fig. 1b).

In addition to its ability to inhibit the MPT, cyclosporin A binds to cytosolic cyclophilin A, and the resulting complex inhibits the Ca2+-regulated protein phosphatase calcineurin (16, 17). The ability of CyA to prevent the cell killing by Bax was not a consequence of the inhibition by CyA of calcineurin. Two other calcineurin inhibitors, cypermethrin A and FK506, alone or in combination with ArA, did not prevent cell killing produced by Bax expression (Table I). FK506 and cypermethrin are inactive against the MPT (18).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Calcineurin inhibitors do not prevent the cell killing by Bax
JtBax1 cells were pretreated for 30 min with the indicated agents. Afterward, muristerone A (1 µM) was added to induce Bax expression. At 8 or 16 h cell viability was determined by both trypan blue exclusion and the MTS assay. Results are the mean ±S.D. of three independent experiments.

The MPT causes the loss of the mitochondrial membrane potential (Delta Psi m) (19). We have used the CyA-inhibitable loss of Delta Psi m to document the MPT in intact cells independently of the effect of the transition on cell viability (18). The fluorescent dye DiOC6(3) localizes to mitochondria as a consequence of Delta Psi m, and the MPT reduces the accumulation of DiOC6(3) as a consequence of the loss of Delta Psi m (20, 21). In JtBax1 cells, CCCP, a proton ionophore that dissipates Delta Psi m, produced a time-dependent loss of DiOC6(3) (Table II), a result indicating the mitochondrial localization of the majority of the dye. Importantly, CyA plus ArA had no effect on the rate or extent of the loss of DiOC6(3) caused by CCCP (Table II), a result demonstrating the specificity of CyA plus ArA in preventing the loss of Delta Psi m as a consequence of the MPT.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Inability of CyA plus ArA to prevent the loss of Delta Psi m produced by CCCP

Treatment of JtBax1 cells with muristerone A produced a steady decline in Delta Psi m, (Fig. 3a), and the time course of the loss of Delta Psi m upon induction of Bax overexpression paralleled that of the loss of viability. Within 4 h, more than 30% of the dye was lost from the cells (Fig. 3a), and 25% of the cells had died (Fig. 2a). Within 8 h, retention of DiOC6(3) was reduced by 65%, and 40% of the cells were dead.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Bax expression causes mitochondrial depolarization that is inhibited by CyA plus ArA but not by Z-DEVD-FMK. In panel a, JtBax1 (closed circles) or JtLacz1 (closed triangles) cells were treated with muristerone A. During the last 30 min of treatment, DiOC6(3) was added. An aliqout of the cells was used for the determination cell-associated DiOC6(3) fluorescence. In panel b, JtBax1 cells were pretreated for 30 min with CyA plus ArA (closed squares) or Z-DEVD-FMK (closed circles). Muristerone A was then added, and the uptake of DiOC6(3) was determined at the times indicated.

The time-dependent loss of DiOC6(3) fluorescence that resulted from the induction of Bax expression was completely inhibited by CyA plus ArA (Fig. 3, a and b). Treatment of JtLacz1 cells with muristerone A had no effect on the retention of the dye over the same time course (Fig. 3a). Consistent with its inability to prevent the loss of viability (Fig. 2b), the caspase inhibitor Z-DEVD-FMK had no effect on Bax-induced mitochondrial depolarization (Fig. 3b), a result that confirms a previous report (8).

Degradation of DNA into oligonucleosomal fragments (180-base pair multiples) is a hallmark of apoptosis(22, 23). Induction of Bax expression produced extensive DNA fragmentation, detectable within 2 h and complete by 4 h (Fig. 4, lanes 1 and 2). There was no DNA fragmentation in JtLacz1 cells treated with muristerone A (Fig. 4, lanes 7 and 8). DNA fragmentation induced by Bax expression was a consequence of the MPT, as shown by its prevention by CyA plus ArA (Fig. 4, lanes 3 and 4). DNA fragmentation also depends on caspase-3 activity, as shown by the ability of Z-DEVD-FMK to prevent the appearance of the characteristic ladder of fragmented DNA (Fig. 4, lanes 5 and 6). Cleavage of the nuclear enzyme PARP by caspase-3 is another prominent indicator of apoptosis (24). Induction of Bax expression resulted in PARP cleavage that was evident within 2 h and complete by 6 h (Fig. 5). CyA plus ArA, as well as Z-DEVD-FMK, prevented this cleavage of PARP (Fig. 5).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 4.   CyA plus ArA prevents the DNA fragmentation produced by Bax. JtBax1 (lanes 1 and 2) or JtLacz1 (lanes 7 and 8) cells were untreated or pretreated for 30 min with either CyA plus ArA (lanes 3 and 4) or Z-DEVD-FMK (lanes 5 and 6). Shown is the DNA fragmentation determined after 2 (odd lanes) or 4 h (even lanes).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 5.   CyA plus ArA inhibits PARP cleavage. JtBax1 cells (5.0 × 106 cells in 24-well plates) were either left untreated or pretreated for 30 min with either CyA plus ArA or Z-DEVD-FMK. Afterward, muristerone A was added to induce Bax expression. At the indicated time points, the cells were harvested, and PARP cleavage was determined by Western blotting.

Induction of Bax expression produced a steady increase in the caspase-3 activity of cytosolic extracts of JtBax1 cells, an effect completely prevented by CyA and ArA (Fig. 6a). As a control, addition of CyA plus ArA to the cytosolic extracts obtained from JtBax1 cells induced with muristerone A had no effect on caspase-3 activity (Fig. 6b), indicating that CyA plus ArA do not inhibit this enzyme directly or any other component necessary for its activation. Z-DEVD-FMK, added to the JtBax1 cells at the time of induction by muristerone A, prevented the increase in caspase-3 activity (Fig. 6b).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6.   CyA and ArA inhibits the caspase-3 activity induced by Bax expression. In panel a, JtBax1 cells (1.0 × 107 cells in 6-well plates) were either left untreated (closed circles) or pretreated for 30 min with CyA and ArA (closed squares). Bax expression was then induced with muristerone A for the indicated times. Cytosolic fractions were prepared and assayed for caspase-3 activity. In panel b, cells were pretreated with Z-DEVD-FMK for 30 min before addition of muristerone A (closed circles). Alternatively, cytosol was prepared from JtBax1 cells induced with muristerone A for the indicated times and assayed for caspase-3 activity in the presence of CyA and ArA (closed squares).

The MPT releases cytochrome c from the intramembranous space (25, 26) and other proteins (24) from the mitochondrial matrix. Cytochrome c released from mitochondria during apoptosis promotes the activation of caspase-3 (27, 28). Bax expression produced a progressive release of cytochrome c to the cytosol of JtBax1 cells and a concomitant decrease in the content of cytochrome c in the mitochondria (Fig. 7a and b). Cytochrome c release to the cytosol and its depletion from the mitochondria was completely inhibited by CyA plus ArA (Fig. 7, a and b). By contrast, Z-DEVD-FMK had no effect on the redistribution of cytochrome c (Fig. 7c).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 7.   The MPT causes release of cytochrome c. JtBax1 cells (1.0 × 107 cells in 6-well plates) were either left untreated or pretreated for 30 min with either CyA and ArA or Z-DEVD-FMK. Muristerone A was then added. At the indicated time, cytosolic and mitochondrial fractions were assayed for cytochrome c by Western blotting.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The data presented above document that the overexpression of Bax induces the MPT, an event that is accompanied by typical features of apoptosis, namely the release of cytochrome c to the cytosol, cleavage of poly(ADP-ribose)-polymerase (PARP), DNA fragmentation, and cell death (Fig. 8). Inhibition of the MPT prevents all manifestations of apoptosis, whereas caspase inhibition prevents PARP cleavage and DNA fragmentation but not cytochrome c release or cell death.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 8.   Mechanism of Bax-induced apoptosis.

Participation of the MPT in our model of apoptosis was shown by the observation that CyA, a known inhibitor of the MPT, in combination with a phospholipase A2 inhibitor, prevents the cell death, as well as the loss of the mitochondrial membrane potential and cytochrome c release. It might be argued that the effect of CyA plus ArA is not necessarily the consequence of an inhibition of the MPT. According to such a scenario, CyA plus ArA interfere with an as yet unidentified mechanism that is both required for the loss of cell viability and is not the MPT. In association with the loss of cell viability, an as yet unidentified mitochondrial injury must be postulated (again not the MPT) that causes, in turn, loss of Delta Psi m and the release of cytochrome c. That CyA plus ArA could act in such an enigmatic manner to inhibit a process that has the same consequences as the MPT, an event that is known to be a target of the action of these compounds, seems highly coincidental.

Bax may induce the MPT in at least two ways. Bax may interact directly with one or more proteins that reside in either the inner or outer mitochondrial membrane and that regulate or constitute the MPT. Alternatively, Bax may itself form a channel that modifies ion fluxes across the mitochondrial membranes (30, 31).

In addition to the loss of viability, Bax expression produced the other typical manifestations of apoptosis, namely caspase activation with DNA fragmentation and PARP cleavage. All of these changes are a likely consequence of the MPT, as they were prevented by CyA plus ArA. PARP is cleaved by caspase-3, and DNA fragmentation has recently been linked to the caspases through activation of DNA fragmentation factor (DFF) (32). In our model, the activation of caspases is clearly the upstream event since Z-DEVD-CMK prevented PARP cleavage and the fragmentation of DNA. The caspase inhibitor, however, did not prevent induction of the MPT and, thus, the loss of cell viability. These results indicate that caspase activation is downstream of the MPT.

The release of cytochrome c from the mitochondria readily accounts for the activation of caspases upon Bax-mediated induction of the MPT. As cytochrome c was retained in the cytosol, it decreased in mitochondria. This redistribution of cytochrome c was prevented by CyA plus ArA, but not by Z-DEVD-CMK. The time course of the release of cytochrome c also paralleled that of the loss of mitochondrial energization. However, the consequences of the release of cytochrome c, namely caspase activation (Fig. 6), PARP cleavage (Fig. 5), and DNA fragmentation (Fig. 4), evolved over a time course that might appear inconsistent with that of the full evolution of the MPT. PARP cleavage was complete within 6 h, a time at which Delta Psi m was reduced by slightly greater than 50% (Fig. 3). We would argue that the release of cytochrome c during the first 6 h following induction of Bax expression and consequent MPT activates caspase-3 to an extent that can account for the degree of PARP cleavage and DNA fragmentation occurring during this period.

Previously, the MPT was discounted as a mechanism of cytochrome c release upon induction of apoptosis by staurosporine in HL-60 cells (27) because the accumulation of cytochrome c in the cytosol preceded a detectable decline in Delta Psi m. It deserves, emphasis that the absence of mitochondrial depolarization, as assessed by the redistribution of fluorescent dyes, does not necessarily imply that the MPT has not occurred. The mitochondrial population reacts heterogeneously to induction of the MPT, with some mitochondria undergoing the MPT very early or very late and some not at all (33). As a consequence there can be a redistribution of membrane-sensitive dyes from depolarized to still polarized mitochondria at earlier time points (34).

The present report has not defined how the MPT is coupled to the loss of cell viability. Importantly, cell death following the MPT is not necessarily the consequence of the loss of an energy-dependent function. Cell killing with inhibition of electron transport is prevented by CyA without restoration of Delta Psi m or ATP levels (35). The link between the MPT and the loss of plasma membrane integrity may involve alterations in the cytoskeleton. The microtubule-associated protein MAP2 binds to porin, thereby linking the mitochondria to the cytoskeleton (36). Although disruption of microtubule structure enhances the MPT (37), it is possible that the opposite is true, that is, the MPT may disrupt the cytoskeleton, a structure that is, in turn, in intimate association with the plasma membrane. Alternatively, the MPT may release mitochondrial matrix proteins, such as mitochondrial phospholipase A2, that may directly damage the plasma membrane (38, 39).

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK-38305 and GM 51430.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Rm. 251, Jefferson Alumni Hall, Thomas Jefferson University, Philadelphia, PA 19107. Tel.: 215-503-5066; Fax: 215-923-2218; E-mail: farber1{at}jeflfin.tju.edu.

1 The abbreviations and other systematic and trivial names used are: MPT, mitochondrial permeability transition; PARP, poly(ADP-ribose)polymerase; CyA, cyclosporin A; ArA, aristolochic acid; DiOC6(3), 3,3'-dihexyloxacarbocyanine; Z-DEVD-FMK, Z-Asp-Glu-Val aspartic acid fluoromethylketone; Delta Psi m, mitochondrial membrane potential; CCCP, carbonyl cyanide m-chlorophenylhydrozone; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; PMS, phenazine methosulfate; PBS, phosphate-buffered saline; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Hassouna, I., Wickert, H., Zimmerman, M., and Gillardon, F. (1996) Neurosci. Lett. 204, 85-88[CrossRef][Medline] [Order article via Infotrieve]
  2. Yin, C., Knudson, C. M., Korsmeyer, S. J., Van Dyke, T. (1997) Nature 385, 637-640[CrossRef][Medline] [Order article via Infotrieve]
  3. Reed, J. C. (1997) Nature 387, 773-776[CrossRef][Medline] [Order article via Infotrieve]
  4. Orrenius, S., Burgess, D. H., Hampton, M. B., Zhivotovsky, B. (1997) Cell Death Differ. 4, 427-428 [CrossRef]
  5. Zamzami, N., Hirsch, T., Dallaporta, B., Petit, P. X., Kroemer, G. (1997) J. Bioenerg. Biomembr. 29, 185-193[CrossRef][Medline] [Order article via Infotrieve]
  6. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. (1993) Cell 74, 609-619[Medline] [Order article via Infotrieve]
  7. Zha, H., Aimé-Sempé, C., Takaaki, S., and Reed, J. C. (1996) J. Biol. Chem. 271, 7440-7444[Abstract/Free Full Text]
  8. Xiang, J., Chao, D. T., and Korsmeyer, S. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14559-14563[Abstract/Free Full Text]
  9. Bernardi, P., Broekemeier, K. M., and Pfeiffer, D. R. (1994) J. Bioenerg. Biomembr. 26, 509-517[Medline] [Order article via Infotrieve]
  10. Fournier, N., Ducet, G., and Crevat, A. (1987) J. Bioenerg. Biomembr. 19, 297-303[Medline] [Order article via Infotrieve]
  11. Crompton, M., Ellinger, H., and Costi, A. (1988) Biochem. J. 255, 357-360[Medline] [Order article via Infotrieve]
  12. Broekemeier, K. M., Dempsey, M. E., Pfeiffer, D. R. (1989) J. Biol. Chem. 264, 7826-7830[Abstract/Free Full Text]
  13. Broekemeier, K. M., and Pfeiffer, D. R. (1995) Biochemistry 34, 16440-16449[Medline] [Order article via Infotrieve]
  14. Imberti, R., Nieminen, A. L., Herman, B., and Lemasters, J. J. (1992) Res. Commun. Chem. Pathol. Pharmacol. 78, 27-38[Medline] [Order article via Infotrieve]
  15. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T.-T., Yu, V. L., Miller, D. K. (1995) Nature 376, 37-43[CrossRef][Medline] [Order article via Infotrieve]
  16. Liu, J., Farmer, J. R., Jr., Lane, W. S., Friedman, J., Weissman, I., Schreiber, S. L. (1991) Cell 66, 807-815[Medline] [Order article via Infotrieve]
  17. Rao, A., Luo, C., and Hogan, P. G. (1997) Annu. Rev. Immunol. 15, 707-747[CrossRef][Medline] [Order article via Infotrieve]
  18. Pastorino, J. G., Simbula, G., Yamamoto, K., Glascott, P. A., Jr., Rothman, R. J., Farber, J. L. (1996) J. Biol. Chem. 271, 29792-29798[Abstract/Free Full Text]
  19. Nieminen, A. L., Saylor, A. K., Tesfai, S. A., Herman, B., Lemasters, J. J. (1995) Biochem. J. 307, 99-106[Medline] [Order article via Infotrieve]
  20. Vayssière, J.-L., Petit, P. X., Risler, Y., and Mignotte, B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11752-11756[Abstract/Free Full Text]
  21. Krippner, A., Matsuno-Yagi, A., Gottlieb, R. A., Babior, B. M. (1996) J. Biol. Chem. 271, 21629-21636[Abstract/Free Full Text]
  22. Wyllie, A. H. (1980) Nature 284, 555-556[Medline] [Order article via Infotrieve]
  23. Wyllie, A. H. (1995) Curr. Opin. Genet. Dev. 5, 97-104[Medline] [Order article via Infotrieve]
  24. Dubrez, L., Savoy, I., Hamman, A., and Solary, E. (1996) EMBO J. 15, 5504-5512[Abstract]
  25. Kantrow, S. P., and Piantadosi, C. A. (1997) Biochem. Biophys. Res. Commun. 232, 669-671[CrossRef][Medline] [Order article via Infotrieve]
  26. Igbavboa, U., Zwizinski, C. W., and Pfeiffer, D. R. (1989) Biochem. Biophys. Res. Commun. 161, 619-625[Medline] [Order article via Infotrieve]
  27. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T. I., Jones, D. P., Wang, X. (1997) Science 275, 1129-1132[Abstract/Free Full Text]
  28. Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997) Cell 90, 405-413[Medline] [Order article via Infotrieve]
  29. Deleted in proof
  30. Schendel, S. L., Xie, Z., Montal, M. O., Matsuyama, S., Montal, M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5113-5118[Abstract/Free Full Text]
  31. Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S. L., Ng, S. C., Fesik, S. W. (1996) Nature 381, 335-341[CrossRef][Medline] [Order article via Infotrieve]
  32. Liu, X., Zou, H., and Wang, X. (1997) Cell 89, 175-184[Medline] [Order article via Infotrieve]
  33. Petronilli, V., Cola, C., Massari, S., Colonna, R., and Bernardi, P. (1993) J. Biol. Chem. 268, 21939-21945[Abstract/Free Full Text]
  34. Gunter, T. E., Gunter, K. K., Sheu, S. S., Gavin, C. E. (1994) Am. J. Physiol. 267, C313-C339[Abstract/Free Full Text]
  35. Pastorino, J. G., Simbula, G., Gilfor, E., Hoek, J. B., Farber, J. L. (1994) J. Biol. Chem. 269, 31041-31046[Abstract/Free Full Text]
  36. Linden, M., and Karlsson, G. (1996) Biochem. Biophys. Res. Commun. 218, 833-836[CrossRef][Medline] [Order article via Infotrieve]
  37. Evtodienko, Y. V., Teplova, V. V., Sidash, S. S., Ichas, F., Mazat, J. P. (1996) FEBS Lett. 393, 86-88[CrossRef][Medline] [Order article via Infotrieve]
  38. Schalkwijk, C. G., Märki, F., Wiesenberg, I., and van den Bosch, H. (1991) J. Lipid Mediators 4, 83-96[Medline] [Order article via Infotrieve]
  39. Aarsman, A. J., de Jong, J. G. N., Arnoldussen, E., Neys, F. W., van Wassenaar, P. D., Van den Bosch, H. (1989) J. Biol. Chem. 264, 10008-10014[Abstract/Free Full Text].


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.